^
Association details:
| Biomarker: | MSI-H/dMMR + TMB-H |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti PD-1 monoclonal antibody in patients with MSI-high and/or high tumor mutational burden for solid malignancies.
Published date:
05/26/2022
Excerpt:
Retrospective analysis of 16 patients (pts) who received 18 CPI-based therapies between October 2017 and February 2022. MSI-H and TMB status was assessed by CARIS, Guardant360 or INVITAE genetic testing…. 15 pts were evaluable for response with an ORR of 33%, including 33% among pts with CRC and 27% for non-CRC malignancies....We identify a higher incidence of SD rates among CRC pts (67% vs. 18% non-CRC).
DOI:
10.1200/JCO.2022.40.16_suppl.e15539
Source:
Title:
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes
Excerpt:
Data and samples from 85 patients with MSI-H mCRC treated with ICIs were gathered….RR was 70.6% in patients with high number of TILs (TILs-H) compared with 42.9% in patients with low number of TILs (odds ratio = 3.20, p = .0291)....A significant correlation between higher TMB and increased number of TILs was shown. A significantly higher activity and better PFS and OS with ICI in MSI-H mCRC…
DOI:
https://doi.org/10.1634/theoncologist.2019-0611
